Table 2.
Mean Biomarker Values Before and After LVAD among Patients with Repeated Longitudinal Measures
| Variables | HF NYHA Class IV (pre-LVAD) | LVAD | p-value |
|---|---|---|---|
| Number of samples | 45 | 92a | |
| Mean number of samples per patient | 1 | 2 | |
| Time after LVAD implant, days | 301.21 (19.09) | ||
| Time before LVAD implant, days | 14.84 (9.66) | ||
| ET-1, pg/ml | 2.96 (2.55, 3.42) | 2.09 (1.82, 2.40) | 0.0003 |
| IL-6, pg/ml | 11.27 (8.60, 14.79) | 5.62 (4.29, 7.35) | <0.0001 |
| TNF-α, pg/ml | 2.17 (1.91, 2.47) | 2.07 (1.81, 2.35) | 0.5373 |
| LPS, EU/ml | 0.29 (0.24, 0.36) | 0.38 (0.31, 0.47) | 0.0091 |
| sCD14, ng/ml | 1,682.6 (1,515.5, 1,868.1) | 1,725.2 (1,569.3, 1,896.5) | 0.7208 |
| Adiponectin, ng/liter | 15,267.6 (12,377.5, 18,832.5) | 10,977.6 (8,861.6, 13,599.0) | 0.0056 |
| CRP, mg/liter | 12.87 (8.74, 18.97) | 6.58 (4.48, 9.64) | 0.0021 |
| Isoprostane, pg/ml | 118.06 (98.32, 141.77) | 75.89 (62.27, 92.48) | <0.0001 |
CRP, C-reactive protein; ET-1, endothelin-1; HF, heart failure; IL-6, interleukin-6; LPS, lipopolysaccharide; LVAD, left ventricular assist device; NYHA, New York Heart Association; sCD14, soluble CD14; TNF-α, tumor necrosis factor-alpha.
Data presented as geometric mean (95% Confidence Interval)
a
All patients provided 1 pre and at minimum 1 post-LVAD sample; 27 patients provided 2 to 4 post-LVAD samples.